Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Multiple Myeloma 3Neuroblastoma 2Testicular Neoplasms 1Teratoma 1Sarcoma 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Ototoxicity 1Osteosarcoma 1Mesothelioma 1Medulloblastoma 1Lymphoma, Large-Cell, Anaplastic 1Liver Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Leukemia 1Hepatoblastoma 1Congenital Abnormalities 1Central Nervous System Neoplasms 1Brain Neoplasms 1Blast Crisis 1

Interventions

Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Has announcements × Lymphoma, Large-Cell, Anaplastic × Clear all
NCT00939770 2020-06-09

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Children's Oncology Group

Phase 1/2 Completed
122 enrolled 24 charts 2 FDA
CNSLymphoid

Neuroblastoma, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡